Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Completed · Not applicable
Conditions studied: Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy, Clinically Significant Prostate Cancer, Transperineal
In brief
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa). With multi-parametric magnetic resonance imaging (mpMRI) we now potentially have a way of increasing the detection of detecting clinically significant prostate cancer (csPCa) while decreasing the detection of non-significant PCa.
Key facts
- Study ID
- NCT03044197
- Run by
- The University of Texas Medical Branch, Galveston
- People needed
- 24
- Starts
- 2017-07-25
- Expected to finish
- 2018-04-12
- Last updated by the study team
- 2019-06-05
Who can join
Age: 18 and older, up to 75. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Males aged 18-75 years old
- PSA >1 ng/ml but <15 ng/ml
- Negative DRE
- Signed informed consent
You may not qualify if…
- Previous prostate biopsy or prostate surgery
- Previous prostate mpMRI
- Contraindication to mpMRI: patients with pacemakers, defibrillators or other implanted electronic devices
- Patients in the Texas Department of Criminal Justice (prisoners)
- Patients with acute urinary symptoms including urinary retention and urinary tract infection
Where it is running
- The University of Texas Medical Branch at Galveston — Galveston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.